Articles from Laverock Therapeutics
Laverock Therapeutics Appoints Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its programmable gene control technology, today announced the appointment of Parker Moss as Chief Executive Officer and member of the Board of Directors, and Paul J. Sekhri as Executive Chairman. Together they will lead Laverock through its transition into a clinical-stage company, including a Series A financing planned for 2027.
By Laverock Therapeutics · Via Business Wire · November 16, 2026
Laverock Therapeutics Reports Key Oncology Research Milestones
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications. The data support lead programme selection and progression towards the clinic.
By Laverock Therapeutics · Via Business Wire · June 10, 2026
Laverock Therapeutics Awarded in Excess of £2.2M Through Two Innovation Grants to Support AI-powered Platform Development and to Expand Therapeutic Programmes Outside of Oncology
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totalling in excess of £2.2M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.
By Laverock Therapeutics · Via Business Wire · June 1, 2026